Josh Schimmer: Would that lead to a potential label amendment as well to include simplified transition dosing?
Michael Weiss: It’s possible. We can €“ we’ve talked about that internally and we’re trying to see if that would be possible, but I couldn’t promise that today.
Josh Schimmer: Okay. Got it. Thanks very much.
Operator: Thank you. We’ll take next question from the line of Ed White with H. C. Wainwright. Please go ahead.
Ed White: Good morning. Thanks for taking my questions. So I was just wondering if you can give us perhaps an idea of the percentage of patients currently on drugs that are taking advantage of the patient assistance programs. And how should we be thinking about the number of patients or percentage of patients on the free drug programs perhaps in the first half of this year versus the second half?
Michael Weiss: Yes. Adam, you want to go ahead that one?
Adam Waldman: Yes. Ed, I don’t have precise numbers in front of me. It’s still pretty early. We do €“ what I can say is that €“ we do expect a higher percent of free goods in the first half of the year and a higher engagement with our programs in the first half of the year as we continue to work through the coverage issues. We’re making good progress, as I mentioned gaining coverage, but it’s still a process. And so we expect a higher percentage in the beginning of the year and that should decrease over time.
Ed White: Okay. Thanks, Adam. And just a question on your sales force. Is your sales force right size now or do you expect to be adding to your footprint?
Adam Waldman: Yes. We feel good about where we are right now. Of course, we will continue to monitor and see what we need as we kind of continue to engage. I would say it’s an €“ it’s something that we would consider if we felt that would help us, but right now we feel like we’re right size for the opportunity and where we’re focused.
Michael Weiss: Yes, I’ll just add to that, Ed, at ACTRIMS, I had a chance to meet with our two business managers that had the east and west coast business and ask them that same question, and everyone feels very comfortable with the size of the team right now.
Ed White: Great, thanks Mike. And my last question, if I may, I always ask this, but can you give us an update on Europe, what you expect the timing will be the six to nine months behind and any thoughts on strategy there? Thanks.
Michael Weiss: Yes. Thanks, Ed. Appreciate you always asking that question for us. Yes, so nothing has changed. We’re still feeling that we’re about 69 months behind in total time from the approval in the U.S. and in terms of strategy, we’re still working hard to identify whether we want to a partner or do it ourselves. We have a little bit of time here, but we’re getting close, probably have some more to say after we have our quarterly conference call, which I assume will be in May timeframe, the first quarter call. So we’ll keep you posted on that, but stay tuned.
Ed White: Great. Thanks for taking my questions.
Michael Weiss: Thanks, Ed.
Operator: Thank you. We’ll take a next question from the line of Prakhar Agrawal with Cantor Fitzgerald. Please go ahead.
Prakhar Agrawal: Hi, good morning, everyone, and thanks for taking my questions. So number one, until the ASP is established for BRIUMVI, are there specific MS center types that might find it economically more attractive to use BRIUMVI over approval, or do you think that it the discounts may not be meaningful enough? You had a couple of follow-ups?
Michael Weiss: Adam, did you get that?
